Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	83.39	127.98	191.44	113.56	144.9	287.31
Short-Term Investments	164.92	88.92	9.95	116.04	74.92	-
Cash & Short-Term Investments	248.31	216.9	201.39	229.6	219.81	287.31
Cash Growth	3.81%	7.70%	-12.28%	4.45%	-23.49%	29.14%
Other Receivables	1.59	0.7	0.06	0.59	0.13	0.01
Receivables	10.84	0.7	0.06	0.59	0.13	0.01
Prepaid Expenses	7.75	11.12	11.32	10.93	6.94	6.44
Restricted Cash	-	0.08	-	-	-	-
Other Current Assets	5.54	3.97	2.56	2.96	2.33	0.18
Total Current Assets	272.44	232.76	215.34	244.07	229.22	293.93
Property, Plant & Equipment	6.79	8.25	12.43	11.43	9.08	3.79
Long-Term Investments	80.32	29.82	-	-	-	-
Other Long-Term Assets	0.72	0.72	0.57	0.57	0.57	0.21
Total Assets	360.26	271.56	228.34	256.07	238.87	297.93
Accounts Payable	5.87	2.5	1.7	0.77	2.39	1.5
Accrued Expenses	26.39	15.49	10.9	12.88	12.71	8.41
Current Portion of Leases	2.91	2.32	2.06	2.36	1.51	1.07
Current Unearned Revenue	5.76	18.99	15.31	14.88	-	-
Other Current Liabilities	0.8	0.75	0.86	0.51	0.54	0.46
Total Current Liabilities	41.73	40.06	30.82	31.39	17.14	11.43
Long-Term Leases	1.87	2.45	4.77	2.72	3.53	0.08
Long-Term Unearned Revenue	8.56	-	33.07	36.86	-	-
Other Long-Term Liabilities	-	0.03	0.11	0.25	0.42	0.34
Total Liabilities	52.16	42.53	68.78	71.22	21.09	11.85
Common Stock	0.01	0.01	0.01	0	0	0
Additional Paid-In Capital	747.44	720	561.43	483.17	414.02	396.35
Retained Earnings	-439.78	-490.83	-401.85	-297.15	-196.08	-110.28
Comprehensive Income & Other	0.45	-0.15	-0.02	-1.18	-0.17	-
Total Common Equity	308.11	229.02	159.57	184.85	217.78	286.08
Shareholders' Equity	308.11	229.02	159.57	184.85	217.78	286.08
Total Liabilities & Equity	360.26	271.56	228.34	256.07	238.87	297.93
Total Debt	4.78	4.77	6.84	5.08	5.04	1.15
Net Cash (Debt)	323.84	241.95	194.56	224.52	214.77	286.16
Net Cash Growth	22.74%	24.36%	-13.34%	4.54%	-24.95%	28.63%
Net Cash Per Share	5.44	4.48	4.42	5.77	5.85	8.55
Filing Date Shares Outstanding	57.12	54.08	46.3	44.15	37.36	36.66
Total Common Shares Outstanding	55.12	54.03	45.92	39.44	36.9	36.58
Working Capital	230.71	192.7	184.52	212.68	212.08	282.51
Book Value Per Share	5.59	4.24	3.47	4.69	5.90	7.82
Tangible Book Value	308.11	229.02	159.57	184.85	217.78	286.08
Tangible Book Value Per Share	5.59	4.24	3.47	4.69	5.90	7.82
Machinery	-	10.31	10.14	8.57	4.93	4.15
Construction In Progress	-	0.12	0.07	0.45	1.61	0.01
Leasehold Improvements	-	2.33	2.29	1.87	0.26	0.21

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q